Benzinga | Apr 5, 2021 07:14AM EDT

Needham Initiates Coverage On Mereo BioPharma Group with Buy Rating, Announces Price Target of $10

Needham analyst Chad Messer initiates coverage on Mereo BioPharma Group (NASDAQ:MREO) with a Buy rating and announces Price Target of $10.